Molecular Partners

Molecular Partners is a clinical-stage biotech company headquartered in Zurich, Switzerland. They are pioneers in the development of DARPin therapeutics, a novel class of custom-built protein drugs. DARPins offer unique advantages compared to traditional antibody-based therapies, including high potency with lower risk of off-target effects, high affinity and specificity, and the ability to target multiple targets at once. Molecular Partners' pipeline focuses on oncology and virology, with a specific focus on developing innovative treatments for cancer and other serious diseases.

Molecular Partners is driven by a strong sense of collaboration and partnership. They foster a diverse and inclusive working environment, emphasizing scientific excellence, respectful teamwork, and personal aspiration. They believe in strong external collaborations to realize the full potential of their DARPin technology and are committed to sharing their science with the world. Their dedication to innovation and their focus on delivering life-changing therapies for patients are central to their mission.

Molecular Partners offers flexible work arrangements for all non-laboratory employees, enabling them to maintain a healthy work-life balance. This includes the option for hybrid schedules, allowing employees to adjust their workdays to accommodate personal needs and interests. The company promotes flexibility to support employees in caring for their families, pursuing personal interests, and fostering a sustainable environment.

Molecular Partners offers comprehensive employee benefits, including health and wellness programs, retirement planning, and flexible work arrangements. Non-laboratory employees are eligible for hybrid work schedules, allowing them to balance work and personal life. The company also prioritizes diversity and inclusion in recruitment and supports sustainability initiatives, such as an employee-led terrace garden.

Molecular Partners is a clinical-stage biotech company dedicated to transforming the lives of people with serious diseases by developing a new class of custom-built protein drugs known as DARPin therapeutics. They believe that DARPin's unique advantages, such as high potency, specificity, and multi-functionality, make them ideal for tackling complex biological challenges and delivering effective treatments for unmet medical needs.

Molecular Partners promotes a culture of partnership and collaboration, both internally and externally. They value scientific excellence and teamwork, fostering an environment where diverse individuals can pursue bold ideas and contribute to their shared goal of providing better treatment options for patients with serious diseases.

Molecular Partners fosters a diverse and inclusive work environment, committed to building a sustainable and equitable workplace. They prioritize creating a welcoming space for all individuals, embracing change, encouraging open communication, and challenging each other's thinking to achieve better outcomes. They actively support employee-led initiatives, such as a terrace garden, and promote a culture of diversity and inclusion through their recruitment process.